Calamos Advisors LLC Has $12,269,000 Stake in Abbott Laboratories (ABT)
Calamos Advisors LLC boosted its stake in Abbott Laboratories (NYSE:ABT) by 0.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 312,118 shares of the healthcare product maker’s stock after buying an additional 54 shares during the period. Calamos Advisors LLC’s holdings in Abbott Laboratories were worth $12,269,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. Nordea Investment Management AB raised its stake in Abbott Laboratories by 13.5% in the second quarter. Nordea Investment Management AB now owns 3,529,762 shares of the healthcare product maker’s stock valued at $138,755,000 after buying an additional 420,435 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Abbott Laboratories by 412.1% in the second quarter. Candriam Luxembourg S.C.A. now owns 701,259 shares of the healthcare product maker’s stock valued at $27,568,000 after buying an additional 564,323 shares in the last quarter. Stoneridge Investment Partners LLC bought a new stake in Abbott Laboratories during the second quarter valued at $11,444,000. National Pension Service raised its stake in Abbott Laboratories by 4.2% in the first quarter. National Pension Service now owns 766,747 shares of the healthcare product maker’s stock valued at $32,073,000 after buying an additional 30,857 shares in the last quarter. Finally, MAI Capital Management raised its stake in Abbott Laboratories by 2.5% in the second quarter. MAI Capital Management now owns 328,683 shares of the healthcare product maker’s stock valued at $12,921,000 after buying an additional 8,170 shares in the last quarter. Hedge funds and other institutional investors own 73.03% of the company’s stock.
Abbott Laboratories (NYSE:ABT) traded up 1.23% during midday trading on Monday, reaching $43.50. 8,285,075 shares of the company’s stock traded hands. Abbott Laboratories has a one year low of $36.00 and a one year high of $46.38. The stock has a market cap of $63.94 billion, a PE ratio of 28.71 and a beta of 0.87. The stock’s 50 day moving average price is $42.27 and its 200-day moving average price is $41.37.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, July 20th. The healthcare product maker reported $0.55 EPS for the quarter, topping the consensus estimate of $0.53 by $0.02. Abbott Laboratories had a return on equity of 15.11% and a net margin of 11.08%. The company earned $5.30 billion during the quarter, compared to the consensus estimate of $5.24 billion. During the same period last year, the company earned $0.52 EPS. Abbott Laboratories’s revenue for the quarter was up 3.2% on a year-over-year basis. Equities analysts predict that Abbott Laboratories will post ($0.01) earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 15th. Investors of record on Friday, October 14th will be issued a $0.26 dividend. The ex-dividend date of this dividend is Wednesday, October 12th. This represents a $1.04 annualized dividend and a yield of 2.39%. Abbott Laboratories’s payout ratio is 68.87%.
Several analysts have recently weighed in on the stock. Barclays PLC reiterated a “buy” rating and issued a $48.00 price objective on shares of Abbott Laboratories in a research note on Saturday, June 18th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research note on Tuesday, July 5th. Jefferies Group boosted their price target on shares of Abbott Laboratories from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, June 14th. BTIG Research restated a “buy” rating and set a $45.00 price target on shares of Abbott Laboratories in a research note on Wednesday, August 10th. Finally, Argus restated a “buy” rating and set a $55.00 price target on shares of Abbott Laboratories in a research note on Thursday, July 28th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Abbott Laboratories presently has an average rating of “Buy” and a consensus price target of $47.02.
In related news, SVP Daniel Gesua Sive Salvadori sold 815 shares of Abbott Laboratories stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $41.71, for a total value of $33,993.65. Following the completion of the sale, the senior vice president now directly owns 59,791 shares in the company, valued at approximately $2,493,882.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Miles D. White acquired 242,547 shares of Abbott Laboratories stock in a transaction that occurred on Monday, July 25th. The stock was acquired at an average price of $43.18 per share, with a total value of $10,473,179.46. Following the completion of the acquisition, the chairman now directly owns 2,010,517 shares in the company, valued at approximately $86,814,124.06. The disclosure for this purchase can be found here. 0.26% of the stock is owned by corporate insiders.
Abbott Laboratories Company Profile
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.
Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.